Evidence map›Paper›PMID 34543681›Full record

ArticleNeurotoxicology2021

YAC128 mouse model of Huntington disease is protected against subtle chronic manganese (Mn)-induced behavioral and neuropathological changes.

Jordyn M Wilcox, Anna C Pfalzer, Adriana A Tienda, Ines F Debbiche, Ellen C Cox, Melissa S Totten, Keith M Erikson, Fiona E Harrison, Aaron B Bowman

Open access · greenAbstract read
In one paragraph

Article in Neurotoxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Pathomechanisms of behavioral abnormalities in Huntington disease: an update.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jordyn M WilcoxDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States; Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, United States.
Anna C PfalzerDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN, United States.
Adriana A TiendaDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Ines F DebbicheVanderbilt Brain Institute, Vanderbilt University, Nashville, TN, United States.
Ellen C CoxDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Melissa S TottenDepartment of Nutrition, University of North Carolina-Greensboro, Greensboro, NC, United States.
Keith M EriksonDepartment of Nutrition, University of North Carolina-Greensboro, Greensboro, NC, United States.
Fiona E HarrisonDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States; Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, United States.
Aaron B BowmanSchool of Health Sciences, Purdue University, West Lafayette, IN, United States. Electronic address: bowma117@purdue.edu.
Vanderbilt University · USVanderbilt University Medical Center · USUniversity of North Carolina at Greensboro · USPurdue University West Lafayette · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
TRAINING PROGRAM IN ENVIRONMENTAL TOXICOLOGYT32ES007028 · NIEHS · VANDERBILT UNIVERSITY · PI F PETER Guengerich, Fiona Edith Harrison · 1985 to 2026
$15.7M
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3M
Gene-Neurotoxicant Interactions in Huntington DiseaseR01ES016931 · NIEHS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BOWMAN, AARON B · 2008 to 2018
$4.5M
Vanderbilt Interdisciplinary Training Program in Alzheimer's DiseaseT32AG058524 · NIA · VANDERBILT UNIVERSITY · PI ANGELA L. JEFFERSON · 2018 to 2026
$3.5M
Manganese exposure susceptibility as a modifier of excitotoxicity in Alzheimer's DiseaseR01ES031401 · NIEHS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BOWMAN, AARON B, HARRISON, FIONA EDITH · 2020 to 2024
$2.7M
Leica Bond RXS10OD023475 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BOYD, KELLI L. · 2018 to 2018
$213k
NCI NIH HHS P30 CA068485NIA NIH HHS T32 AG058524NICHD NIH HHS P50 HD103537NIEHS NIH HHS R01 ES016931NIEHS NIH HHS R01 ES031401NIEHS NIH HHS T32 ES007028NIH HHS S10 OD023475
6 · The paper itself

Abstract

Manganese (Mn) is an essential micronutrient but excessive levels induce neurotoxic effects. Increasing evidence suggests a deficit of bioavailable Mn in Huntington disease (HD), an inherited neurodegenerative disease characterized by motor and cognitive disturbances. Previous studies have shown rescue of some molecular HD phenotypes by acute Mn exposure. This study simultaneously examined the potential for chronic Mn exposure to attenuate HD behavioral phenotypes, and for the HD genotype to offer protection against detrimental effects of chronic Mn exposure. In two independent studies a chronic Mn exposure paradigm was implemented in the YAC128 mouse model of HD and behavior was assessed at several timepoints. Study 1 exposed WT and YAC128 mice to twice weekly subcutaneous injections of 0, 5, 15, or 50 mg/kg MnCl[2] tetrahydrate from 12 to 32 weeks of age. A promising protective effect against motor coordination decline in 5 mg/kg MnCl[2] tetrahydrate-treated YAC128 mice was detected. Study 2 thus exposed WT and YAC128 mice to either 0 or 5 mg/kg MnCl[2] tetrahydrate from 12 to 52 weeks of age (with a partial randomized treatment crossover at 31 weeks). The same protective effect was not observed under these conditions at higher statistical power. We report subtle toxicological changes in exploratory behavior and total activity induced by chronic Mn exposure in WT mice only, despite similar total increases in brain Mn in WT and YAC128 mice. Further, chronic Mn treatment resulted in a 10-12 % decrease in striatal NeuN positive cell density in WT mice but not YAC128 mice, despite vehicle cell counts already being reduced compared to WT mice as expected for the HD genotype. The subtle changes observed in specific outcome measures, but not others, following long-term low-level Mn exposure in WT mice delineate the neurobehavioral and neuropathological effects at the threshold of chronic Mn toxicity. We conclude that these chronic low-dose Mn exposures do not significantly rescue behavioral HD phenotypes, but YAC2128 mice are protected against the subtle Mn-induced behavioral changes and decreased striatal neuron density observed in Mn-exposed WT mice.

Indexed as

AnimalsDisease Models, AnimalDose-Response Relationship, DrugFemaleHand StrengthHuntington DiseaseMaleManganeseMaze LearningMiceMice, TransgenicNeuroprotective AgentsOpen Field TestRotarod Performance TestManganeseNeuroprotective AgentsBehaviorHuntington diseaseManganesestriatumYAC128

Identifiers

PMID34543681
PMCPMC8761387
OpenAlexW3200813910

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.